1. Home
  2. EIX vs BIIB Comparison

EIX vs BIIB Comparison

Compare EIX & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Edison International

EIX

Edison International

HOLD

Current Price

$55.54

Market Cap

21.3B

Sector

Utilities

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$226.10

Market Cap

29.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EIX
BIIB
Founded
1886
1978
Country
United States
United States
Employees
13725
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.3B
29.9B
IPO Year
1994
1996

Fundamental Metrics

Financial Performance
Metric
EIX
BIIB
Price
$55.54
$226.10
Analyst Decision
Hold
Buy
Analyst Count
13
25
Target Price
$72.09
$206.83
AVG Volume (30 Days)
6.5M
665.6K
Earning Date
04-28-2026
04-29-2026
Dividend Yield
5.17%
N/A
EPS Growth
248.94
N/A
EPS
1.37
2.15
Revenue
$19,317,000,000.00
$9,890,600,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.17
N/A
P/E Ratio
$40.11
$101.89
Revenue Growth
9.76
2.22
52 Week Low
$52.00
$135.39
52 Week High
$81.62
$225.80

Technical Indicators

Market Signals
Indicator
EIX
BIIB
Relative Strength Index (RSI) 33.81 56.12
Support Level $54.48 $184.50
Resistance Level $61.17 $225.80
Average True Range (ATR) 1.82 5.10
MACD 0.09 -0.25
Stochastic Oscillator 17.09 65.48

Price Performance

Historical Comparison
EIX
BIIB

About EIX Edison International

Edison International is the parent company of Southern California Edison, an electric utility that distributes electricity to 5 million customers in a 50,000-square-mile area of Southern California, excluding Los Angeles. Edison Energy owns interests in nonutility businesses that deal in energy-related products and services. In 2014, Edison International sold its wholesale power generation subsidiary Edison Mission Energy out of bankruptcy to NRG Energy.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: